论文部分内容阅读
目的观察双嘧达莫治疗儿童急性上呼吸道感染的疗效及安全性。方法采用随机对照研究,将232例急性上呼吸道感染患儿分成2组。观察组116例,口服双嘧达莫3 mg/(kg.d),3次/d;对照组116例,口服利巴韦林10 mg/(kg.d),4次/d,2组疗程均为3d。结果观察组总有效率为92.2%(107/116),对照组总有效率为70.6%(82/116),2组总有效率比较:差异有统计学意义(P<0.01)。结论双嘧达莫治疗儿童急性上呼吸道感染疗效确切,安全可靠。
Objective To observe the efficacy and safety of dipyridamole in children with acute upper respiratory tract infection. Methods A randomized controlled study was conducted to divide 232 children with acute upper respiratory tract infection into two groups. In the observation group, 116 cases were treated with dipyridamole 3 mg / (kg · d) orally for 3 times daily, while 116 cases in the control group were orally administered with ribavirin 10 mg / (kg · d), 4 times / d, The course of treatment is 3d. Results The total effective rate was 92.2% (107/116) in the observation group and 70.6% (82/116) in the control group. The total effective rate in the two groups was statistically significant (P <0.01). Conclusion Dipyridamole treatment of acute upper respiratory tract infection in children is effective, safe and reliable.